Lupus clinical trials at UCSF
3 in progress, 1 open to eligible people
Lupus is a disease where your body's defense system attacks your own tissues. UCSF is studying a medicine called Obinutuzumab in teenagers with severe lupus kidney problems. UCSF is also checking the safety of this drug in children.
Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
open to eligible people ages 5-17
This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to <12 with LN.
San Francisco, California and other locations
IMPT-514 in Active Refractory Systemic Lupus Erythematosus (SLE)
Sorry, not currently recruiting here
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-514, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with active, refractory lupus nephritis and systemic lupus erythematosus. IMPT-514 treatment consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide. Individual participants will remain in the active post-treatment period for approximately 1 year. Participants will continue in long-term follow-up for 15 years from treatment.
San Francisco, California and other locations
VIBRANT: VIB4920 for Active Lupus Nephritis
Sorry, in progress, not accepting new patients
This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).
San Francisco, California and other locations
Our lead scientists for Lupus research studies include David Wofsy, M.D. Jonathan Graf.
Last updated: